Detailed Narrative
Strategic Reorganization into Two Segments
IQVIA is simplifying its organizational structure in 2026, moving from three segments to two: Commercial Solutions and R&DS. This change aims to strengthen collaboration, enhance efficiency, and align with evolving client purchasing behaviors. The former CSMS segment, with $788 million in FY25 revenue, is now incorporated into Commercial Solutions. Additionally, $674 million of clinically oriented real-world offerings from the former TAS segment have been moved to R&DS, reflecting their closer ties to clinical trial dynamics. This recast has a negligible impact on segment growth rates.
AI Leadership and Strategic Partnerships
IQVIA announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as its preferred agentic cloud provider to accelerate digital transformation in life sciences. The company was recognized by Everest Group as the #1 leader in generative AI for life sciences. IQVIA has been working with NVIDIA for over a year to embed AI agents into workflows, deploying over 150 agents across more than 30 use cases in clinical and commercial operations. This long-standing investment in AI is now gaining significant momentum with clients, particularly large pharma.
AI as an Opportunity, Not a Threat
Management strongly emphasized that AI agentification is a positive for IQVIA's business, not a challenge. They highlighted three key requirements for AI agents: significant ready-to-consume data at scale, deep domain expertise, and technology. IQVIA possesses proprietary, dynamic, regulatory-compliant healthcare data and decades of industry expertise that are difficult to replicate. While some lower-level consulting work might be displaced, the company is seeing increased demand for new AI-enabled offerings like Data-as-a-Service (DaaS) and believes AI will augment, not replace, its services.
Strong Demand Indicators in R&DS
Despite earlier macroeconomic headwinds🌐, demand indicators for R&DS became more favorable as 2025 progressed. The qualified pipeline is up approximately 10% year-over-year across all customer segments. RFP flow grew double digits year-over-year, with the largest gains in large pharma and emerging biotech and pharma (EBP). Win rates improved by several percentage points year-over-year, and EBP funding was strong in Q4, reaching $33 billion according to BioWorld.
Commercial Solutions Performance
The Technology & Analytics Solutions (TAS) business, now part of Commercial Solutions, performed well in Q4, achieving better-than-expected results despite anticipated tougher year-over-year comparisons. TAS delivered 9.8% reported growth and 7.1% constant currency growth, highlighting the resilience of IQVIA's broader commercial portfolio. Demand for AI-driven innovations is gaining momentum with clients, with several top pharma companies selecting IQVIA for comprehensive AI-enabled information and analytics solutions.
Acquisition of Cedar Gate Technologies
In the fourth quarter, IQVIA acquired Cedar Gate Technologies, enhancing its capabilities in patient solutions and payer analytics. Cedar Gate transforms healthcare data into insights for improved patient outcomes and provides analytics to payers, utilizing 4 petabytes of data covering approximately 60 million lives. This acquisition expands IQVIA's solutions in the payer-provider analytics space, an area where the company previously lacked significant scale in the U.S.